Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Iradimed (NASDAQ:IRMD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.
Earnings and Valuation
This table compares Vivos Therapeutics and Iradimed”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $13.80 million | 0.62 | -$13.58 million | ($7.03) | -0.36 |
| Iradimed | $65.56 million | 9.74 | $17.19 million | $1.46 | 34.53 |
Iradimed has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Institutional and Insider Ownership
26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 92.3% of Iradimed shares are held by institutional investors. 9.6% of Vivos Therapeutics shares are held by company insiders. Comparatively, 37.1% of Iradimed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Vivos Therapeutics and Iradimed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -85.90% | -652.32% | -98.95% |
| Iradimed | 26.83% | 24.71% | 20.86% |
Analyst Ratings
This is a summary of recent ratings for Vivos Therapeutics and Iradimed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Iradimed | 0 | 0 | 3 | 0 | 3.00 |
Vivos Therapeutics currently has a consensus target price of $6.60, suggesting a potential upside of 160.87%. Iradimed has a consensus target price of $60.00, suggesting a potential upside of 19.02%. Given Vivos Therapeutics’ higher possible upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than Iradimed.
Summary
Iradimed beats Vivos Therapeutics on 11 of the 13 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
About Iradimed
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
